Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2020-10-14 Regulatory Filings
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on October 14, 2020, and states it is a "Release of an ad hoc announcement pursuant to Art. 53 KR". The content details Polyphor receiving a significant, non-dilutive funding award (up to USD 18.44 million) from CARB-X to support an antibiotic development program. This announcement concerns fundraising, financing, and strategic development milestones, which aligns directly with the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific financing event.
2020-10-14 English
Polyphor announces closing of Fosun Pharma licensing agreement for balixafortide in China and receipt of $15 million upfront payment
Regulatory Filings Classification · 99% confidence The document is titled 'News Details' and is released as an 'Ad-hoc' announcement on September 29, 2020, pursuant to 'Art. 53 KR'. The content details the closing of an exclusive licensing agreement with Fosun Pharma and the receipt of an upfront payment ($15 million). This type of announcement, reporting a significant corporate event (a major licensing deal and associated financing/payment), is typically classified as a general regulatory announcement or a capital/financing update. Since it specifically details a licensing agreement and the receipt of funds related to that agreement, it strongly aligns with 'Capital/Financing Update' (CAP) as it involves a significant financial transaction and milestone structure. However, given the context of a press release announcing a major corporate event that isn't a standard periodic report (10-K, IR, ER), and the use of 'Ad-hoc' release language common in European markets, it could also fit 'Regulatory Filings' (RNS) if CAP is too specific. Given the explicit mention of receiving $15 million upfront payment and future milestone payments, CAP is the most precise fit among the specific options, as it relates directly to capital structure/financing activities resulting from a deal. It is not an ER, IR, 10-K, or CT. It is a specific corporate action announcement, making CAP the best fit over the general RNS.
2020-09-29 English
Polyphor to present at the H.C. Wainwright Global Investment Conference
Regulatory Filings Classification · 100% confidence The document is a short press release dated September 11, 2020, announcing that Polyphor AG will present at the H.C. Wainwright Global Investment Conference. It details the date, time, and location (virtual) of the presentation and provides contact information. This type of announcement, which informs the market about participation in an external investor event, is best classified as a general Investor Presentation announcement or, more broadly, a Regulatory Filing (RNS) if a more specific category doesn't fit. Since it is an announcement about future participation in a conference where an overview of the company and pipeline will be given, it relates closely to investor relations activities. However, it is not the presentation itself (IP) nor a formal earnings release (ER). Given the context of an 'ad hoc announcement' regarding participation in a major investment conference, it functions as a general market communication. Since there is no specific category for 'Conference Presentation Announcement,' and it is not a formal report, the most appropriate general category for non-standard, timely corporate news is RNS, or potentially IP if we interpret the announcement as promoting the upcoming presentation materials. Given the structure (short news release about an event), RNS (Regulatory Filings/General Announcement) is the safest fallback, but since the content is purely about an investor event, I will check if 'IP' (Investor Presentation) applies. IP is defined as the detailed presentation itself. This is an announcement *about* the presentation. Therefore, RNS is the most accurate fit for this type of short, ad-hoc market notice that doesn't fit the other specific categories like ER, DIV, or CAP.
2020-09-11 English
Polyphor announces financial results for the first half 2020
Earnings Release Classification · 100% confidence The document is titled "Polyphor announces financial results for the first half 2020" and contains key financial highlights (Profit and Loss, Balance Sheet) for the period ending June 30, 2020. This content structure strongly indicates a report covering a period shorter than a full year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it is presented as a news release (Ad-hoc announcement), the core content is the detailed financial summary for the half-year, making 'IR' the most accurate classification over a simple 'ER' (Earnings Release, which is usually just highlights) or 'RPA' (Report Publication Announcement, which typically just announces the availability of a separate report). Since the document contains the actual financial tables and detailed commentary on the half-year performance, it is classified as the report itself. H1 2020
2020-09-03 English
Polyphor and Fosun Pharma announce exclusive licensing agreement for balixafortide in China
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on August 31, 2020, pursuant to Art. 53 KR (likely referring to Swiss stock exchange regulations for ad-hoc disclosures). The content details an exclusive licensing agreement between Polyphor and Fosun Pharma regarding a drug (balixafortide), including financial terms (upfront payment, milestones, royalties) and strategic rationale. This type of announcement, concerning a significant business transaction or partnership that is material to the company's operations and valuation, is best classified as a general regulatory announcement or a specific corporate action announcement. Since there is no specific code for 'Licensing Agreement' or 'Partnership Announcement', and it is a formal, time-sensitive disclosure, it falls under the broad category of regulatory filings or a specific corporate event. Given the nature of the announcement (a major business deal), it is not a standard Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a material corporate event disclosure. In the provided schema, 'RNS' (Regulatory Filings) serves as the general category for miscellaneous regulatory announcements that don't fit elsewhere. However, since this is a major corporate transaction announcement, it often relates to capital structure or strategic changes. Since it is not explicitly about capital raising (CAP) or M&A (TAR), the most appropriate general regulatory category is RNS, or potentially a specific type of corporate action if one were available. Given the options, RNS is the safest fit for a non-standard, material ad-hoc disclosure.
2020-08-31 English
Polyphor announces second positive Data Safety Monitoring Board recommendation to continue Phase III FORTRESS study without modifications
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on August 3, 2020, and states it is a "Release of an ad hoc announcement pursuant to Art. 53 KR." It details a clinical trial update (Phase III FORTRESS study recommendation from the DSMB) and includes forward-looking statements and contact information typical of a press release. This type of announcement, which is a general regulatory disclosure that doesn't fit the specific categories like ER (Earnings Release), IR (Interim Report), or CAP (Financing Update), falls best under the general regulatory disclosure category. Since it is a general regulatory announcement that doesn't fit the more specific categories (like ER, IR, DIV, etc.), the most appropriate fallback category is Regulatory Filings (RNS). It is not a full report (10-K, AR, IR) nor a presentation (IP), nor a management discussion (MDA).
2020-08-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.